


# Best Pharmaceuticals for Children Act



OMB # 0925-0648

Expiration Date: 6/30/2024

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

**Thank you for attending the 2021 BPCA Stakeholders Meeting! Please take 5 minutes to evaluate this meeting. Our goal is to obtain feedback so that we can improve the next meeting.**

## MEETING CONTENT

On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” please rate the following sessions (leave blank if you skipped a particular session):

### NICHD Update-COVID Response (Tamburro)

1	2	3	4	5
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

### Additional Comments

## Advancing Pediatric Therapeutics: Regulatory Perspective (Mulugeta)

1

2

3

4

5

Additional Comments

## Accomplishments and Challenges in Pediatric Drug Development: Experience of the Pediatric Trials Network (Greenberg)

1

2

3

4

5

Additional Comments

# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute  
of Child Health and Human Development




**Please provide your feedback regarding the roundtable discussion on December 2.**


**Which brainstorming session did you attend?**

- 1) Optimal Trial Development
- 2) Developmental Status of Organ Systems
- 3) Integrating Data
- I did not attend a brainstorming session.

**Please provide your feedback regarding the brainstorming sessions on December 3.**

# Best Pharmaceuticals for Children Act

 Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## BPCA FRAMEWORK TO ENABLE PEDIATRIC DRUG DEVELOPMENT

*A core theme of this meeting was the development of a framework to enable pediatric drug development. We would like your thoughts on the utility of the framework, suggestions, and input on how it can be improved and enhanced in the months and years to come.*

**Please provide your feedback on the BPCA Framework to Enable Pediatric Drug Development.**

**On a scale of 1 to 5, with 5 being “excellent,” and 1 being “poor,” what is your overall rating of the meeting?**

1	2	3	4	5
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**How can we improve the next BPCA Stakeholders Meeting?**

**Please provide any additional comments here.**

# Best Pharmaceuticals for Children Act



Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## FUTURE ACTIVITIES

**If you are not on the BPCA Stakeholders mailing list, would you like to be added?**

Yes

No

This evaluation is anonymous, so we are unable to reply directly to any questions you include on this form. If you would like a response to your question, please email [bpca@infinityconferences.com](mailto:bpca@infinityconferences.com).

Thank you for your participation!